Use of mouse models of allergic rhinitis to study the upper and lower airway link

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 1, 2004, Pages 11-16

  McCusker, Christine T ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Allergy; Animal models; Asthma; Immune tolerance; Rhinitis; United airways

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 13;

ALLERGIC REACTION; ALLERGIC RHINITIS; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ASTHMA; BRONCHUS HYPERREACTIVITY; CYTOKINE PRODUCTION; DENDRITIC CELL; IMMUNOSTIMULATION; LOWER RESPIRATORY TRACT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; T LYMPHOCYTE; TH2 CELL; UPPER RESPIRATORY TRACT;

ALLERGENS; ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RESPIRATORY SYSTEM; RHINITIS, ALLERGIC, PERENNIAL;

EID: 4143108932     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200402000-00004     Document Type: Review

References (63)

1. Koh YY, Kim CK, The development of asthma in patients with allergic rhinitis. Curr Opin Allergy Clin Immunol 2003; 3:159-164.
2. Boulay ME, Boulet LP. The relationship between atopy, rhinitis and asthma: pathophysiological considerations. Curr Opin Allergy Clin Immunol 2003; 3:51-55.
3. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 2003; 111:1171-1183.
4. Braunstahl GJ, Hellings PW. Allergic rhinitis and asthma: the link further unraveled. Curr Opin Pulm Med 2003; 9:46-51.
5. Campanella SG, Asher MI. Current controversies: sinus disease and the lower airways. Ped Pulmon 2001; 31:165-172.
6. Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects. Thorax 2000; 55 (Suppl 2):s26-s27.
7. Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol 2001; 108:s9-s15.
8. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109:419-425. The authors used data from the Tuscon epidemiologic study of obstructive lung diseases and conclude that rhinitis is a significant risk factor for asthma in adults, Severity of nasal symptoms correlated with increased risk for asthma.
9. Hurwitz B. Nasal pathology impacts bronchial reactivity and asthmatic patients with allergic rhinitis. J Asthma 1997; 34:427-431.
10. Adams R, Fuhlbrigge A, Ja S, Weiss S. Intranasal steroids and the risk for emergency department visits for asthma. J Allergy Clin Immunol 2002; 109:36-42.
11. Crystal Peters J, Neslusan C, Crown W, Amelito Torres M. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:57-62.
12. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT Study). J Allergy Clin Immunol 2002; 109:251-256.
13. Fuhlbrigge AL, Adams RJ. The effect of treatment of allergic rhinitis on asthma morbidity, including emergency department visits. Curr Opin Allergy Clin Immunol 2003; 3:29-32.
14. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161:2051-2057.
15. Alvarez MJ, Olaguibel JM, Garcia BE, et al. Airway inflammation in asthma and perennial allergic rhinitis: relationship with nonspecific bronchial responsiveness and maximal airway narrowing. Allergy 2000; 55:531-539.
16. Polosa R, Ciamarra I, Magnano G, et al. Bronchial hyperresponsiveness and airways inflammation markers in nonasthmatics with allergic rhinitis. Eur Respir J 2000; 15:30-35.
17. Foresi A, Pelucchi A, Herson G, Mastropasqua B, et al. Once daily fluticasone proprionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98:274-282.
18. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000; 192:455-462.
19. von Mutius E. Environmental factors influencing the development and progression of pediatric asthma. J Allergy Clin Immunol 2002; 109:s525-s532.
20. Vinuya RZ. Upper airway disorders and asthma: a syndrome of airway inflammation. Ann Allergy Asthma Immunol 2002; 88:s8-s15.
21. Ernst P, Cormier Y. Relative scarcity of asthma and atopy among rural adolescents raised on a farm. Am J Respir Crit Care Med 2000;, 161:1563-1566.
22. Filipiak B, Heinrich J, Schafer T, et al. Farming, rural lifestyle and atopy in adults from southern Germany: results from the MONICA/KORA study Augsburg. Clin Exp Allergy 2001; 31:1829-1838.
23. Braun-Fahrlander C. The role of the farm environment and animal contact for the development of asthma and allergies. Clin Exp Allergy 2000; 31:1799-1803.
24. Kaufmann F, Oryszczyn MP, Maccario J. The protective role of country living on skin prick tests, immunoglobulin E and asthma in adults from the Epidemiological study on the Genetics and Environment of Asthma, Bronchial Hyper-responsiveness and Atopy. Clin Exp Allergy 2002; 32:379-386.
25. Portengen L, Sigsgaard T, Omland O, et al. Low prevalence of atopy in young Danish farmers and farming students born and raised on a farm. Clin Exp Allergy 2002; 32:247-253.
26. Braun-Farlander C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002; 347:869-877. In this study endotoxin levels were measured in the mattresses of children and correlated with incidence of atopic rhinitis, asthma and atopic sensitization. The study found a significant inverse correlation between endotoxin exposure (level) and frequency of atopic disease.
27. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999; 17:255-281.
28. Mojtabavi N, Dekan G, Stingl G, Epstein MM. Long-lived Th2 memory in experimental allergic asthma. J Immunol 2002; 169:4788-4796. In a mouse model of asthma, allergic phenotype could be recalled 400 days after original challenge suggested long-term allergenic memory cells.
29. Salek-Ardakani S, Song J, Halteman BS, et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003; 198:315-324. In an animal model of asthma, these authors demonstrated the importance of OX40-OX40L interaction in propagation of T-cell recall (memory) responses to antigen. Blocking of this interaction resulted in suppression of T-cell accumulation in airways, airway eosinophilia and hyperreactivity.
30. Kanaizumi E, Shirasaki H, Sato J, et al. Establishment of animal model of antigen-specific T lymphocyte recruitment into nasal mucosa. Scand J Immunol 2002; 56:376-382. Using an adoptive transfer model of ovalbumin-specific transgenic T cells, this study demonstrates that upper airway allergic phenotype can be transferred via Th2 cells but not Th1 or Th0 cells in the same way as in asthma models, supporting the upper and lower airway link.
31. Macaubas C, Holt P. Regulation of cytokine production in T-cell responses to inhalant allergen: GATA-3 expression distinguishes between Th1 and Th2-polarized immunity. Int Arch Allergy Immunol 2001; 124:176-179.
32. Hahn C, Teufel M, Herz U, et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J Allergy Clin Immunol 2003; 111:1361-1369. In this animal model airway sensitization was achieved using exclusive mucosal sensitization and challenge. Using specific IL-13/IL-4 inhibitor prior to sensitization inhibited development of the allergic phenotype. Once allergy was established, however, this mode of inhibition was not effective. This study suggests that mechanisms of allergic primary and secondary responses are distinct.
33. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9:582-588.
34. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003; 111:1863-1874.
35. Wills-Karp M, Chiaramonte M. Interleukin-13 in asthma. Curr Opin Pulm Med 2003; 9:21-27. This is an excellent comprehensive review of recent literature about IL-13 and its role in asthma.
36. Holt PG, Rowe J, Loh R, Sly PD. Developmental factors associated with risk for atopic disease: implications for vaccine strategies in early childhood. Vaccine 2003; 21:3432-3435.
37. Steerenberg PA, Withagen CE, Dormans JA, et al. Adjuvant activity of various diesel exhaust and ambient particles in two allergic models. J Toxicol Environ Health 2003; 66:1421-1439. Two models of allergic airway disease were compared in this study examining the effects of diesel exhaust and ambient particles. The authors noted differences in allergic responses depending upon the animal model used and showed pollutant particles can act as adjuvants, increasing levels of allergen-specific IgE and inflammation in a mouse model of allergic airways disease.
38. Boulay ME, Boulet LP. Lower airways inflammatory responses to repeated very-low-dose allergen challenge in allergic rhinitis and asthma. Clin Exp Allergy 2002; 32:1441-1447.
39. Schmitz N, Kurrer M, Kopf M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 2003; 33:991-1000.
40. Canonica GW. Introduction to nasal and pulmonary allergy cascade. Allergy 2002; 57 (Suppl 75):8-12.
41. Saito H, Matsumoto K, Denburg AE, et al. Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequence of IL-5 deficiency. J Immunol 2002; 168:3017-3023.
42. Hogan SP, Matthaei KI, Young JM, et al. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in Balb/c mice independently of IL-4 and IL-5. J Immunol 1998; 161:1501-1509.
43. Hussain I, Randolph D, Brody SL, et al. Induction, distribution and modulation of upper airway allergic inflammation in mice. Clin Exp Allergy 2001; 31:1048-1059.
44. Hellings PW, Hessel EM, Van den Oord JJ, et al. Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyperreactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy 2001; 31:782-790.
45. Iwasaki M, Saito K, Takemura M, et al. TNF-α contributes to the development of allergic rhinitis in mice. J Clin Allergy Immunol 2003; 112:134-140. In a model of allergic rhinitis the role of tumor necrosis factor-α was assessed. Tumor necrosis factor-α knockout mice had reduction in levels of ovalbumin-specific IgE, decreased inflammation and symptom scores when compared with wild-type. The authors suggest that tumor necrosis factor-α may be important for stimulation of adhesion molecules important for recruitment of inflammatory cells.
46. Oh JW, Seroogy CM, Meyer EH, et al. CD4 T-helper cell engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J Allergy Clin Immunol 2002; 110:460-468. CD4+ T cells expressing IL-10 specifically inhibited airway hyperreactivity and eosinophilia in both BALB/c and reconstituted severe combined immune deficiency mice. This effect was neutralized by anti-IL-10 antibody. These data support a important regulatory role for IL-10 cytokine.
47. Adkins B, Bu Y, Guevara P. Murine neonatal CD4+ lymph node cells are highly deficient in the development of antigen-specific Th1 function in adoptive adult hosts. J Immunol 2002; 169:4998-5004.
48. McCusker CT, Chicoine M, Hamid Q, Mazer B. Site-specific sensitization in a murine model of allergic rhinitis: role of the upper airway in lower airways disease. J Allergy Clin Immunol 2002; 110:891-898.
49. Swirski FK, Gajewskla BU, Alvarez D, et al. Inhalation of harmless antigen (ovalbumin) elicits immune activation but divergent immunoglobulin and cytokine activities in mice. Clin Exp Allergy 2002; 32:411-421.
50. Akbari O, Stock P, DeKruyff RH, Umetsu DT. Mucosal tolerance and immunity: regulating the development of allergic disease and asthma. Int Arch Allergy Immunol 2003; 130:108-118. A comprehensive overview of mucosal immunity and potential mechanisms in the development of mucosal tolerance are explored.
51. Wang Y, McCusker C. Lower airways hyperresponsiveness following isolated upper airway allergen challenge in a murine model of asthma and allergic rhinitis. Abstract World Allergy Organization Congress XV111. Allergy Clin Immunol Int 2003; Suppl 1:142.
52. Ikeda RK, Nayar J, Cho JY, et al. Resolution of airway inflammation following ovalbumin inhalation: comparison of ISS DNA and corticosteroids. Am J Respir Cell Mol Biol 2003; 28:655-663.
53. Winkler B, Baier K, Wagner S, et al. Mucosal tolerance as therapy of type 1 allergy: intranasal recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002; 32:30-36.
54. Takabayashi K, Libet L, Chishilm D, et al. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J Immunol 2003; 170:3898-3905.
55. Swirksi FK, Sajic D, Robbins CS, et al. Chronic exposure to innocuous antigen in sensitized mice leads to suppressed airway eosinophilia that is reversed by granulocyte macrophage colony-stimulating factor. J Immunol 2002; 169:3499-3506.
56. Tsitoura DC, DeKruyff RH, Lamb JR, Umetsu DT. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol 1999; 163:2592-2600.
57. Tsitoura DC, Blumenthal RL, Berry G, et al. Mechanisms preventing allergen-induced airways hyperreactivity: role of tolerance and immune deviation. J Allergy Clin Immunol 2000; 106:239-246.
58. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2:725-731.
59. Tsitoura DC, Yeung VP, DeKruyff RH, Umetsu DT. Critical role of B cells in the development of T cell tolerance to aeroallergens. Int Immunol 2002; 14:659-667.
60. Hall G, Lung L, Lamb JR, Jarman ER. Kinetics and mode of peptide delivery via the respiratory mucosa determine outcome of activation versus Th2 immunity in allergic inflammation of the airways. J Allergy Clin Immunol 2002; 110:883-890. In this study the authors demonstrated the importance of antigen delivery for stimulation of active airway immune responses.
61. Hall G, Houghton CG, Rahbek JU, et al. Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodominant peptide is linked to IL-10 production. Vaccine 2003; 21:549-561. The effects of mucosal antigen stimulation in an established sensitized animal were studies using immunodominant peptides and a particle-delivery system. Mode of antigen delivery was important in inducing increases in IL-10 associated with the tolerant phenotype.
62. Braunstahl GJ, Fokkens WJ, Overbeek SE, et al. Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin Exp Allergy 2003; 33:579-587.
63. Graffi SJ, Dekan G, Stingl G, Epstein MM. Systemic administration of antigen-pulsed dendritic cells induces experimental allergic asthma in mice upon aerosol antigen rechallenge. Clin Immunol 2002; 103:176-184.